RPAM
NKTR icon

Rhenman & Partners Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Rhenman & Partners Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.25M Buy
+59,000
New +$3.36M 0.52% 63
2023
Q1 		– Sell
-36,667
Closed -$1.24M – 92
2022
Q4 		$1.24M Hold
36,667
– – 0.13% 89
2022
Q3 		$2.07M Hold
36,667
– – 0.22% 84
2022
Q2 		$2.09M Sell
36,667
-4,259
-10% -$269K 0.24% 78
2022
Q1 		$3.31M Sell
40,926
-22,407
-35% -$3.32M 0.33% 75
2021
Q4 		$13.3M Hold
63,333
– – 0.88% 42
2021
Q3 		$17.1M Hold
63,333
– – 1.2% 39
2021
Q2 		$16.3M Sell
63,333
-23,813
-27% -$6.59M 1.11% 39
2021
Q1 		$26.1M Sell
87,146
-2,854
-3% -$888K 1.82% 17
2020
Q4 		$22.9M Buy
90,000
+23,333
+35% +$6.03M 1.87% 16
2020
Q3 		$16.6M Buy
66,667
+14,000
+27% +$4.4M 1.48% 29
2020
Q2 		$18.3M Sell
52,667
-19,000
-27% -$5.93M 1.98% 13
2020
Q1 		$19.2M Sell
71,667
-1,666
-2% -$515K 2.69% 7
2019
Q4 		$23.7M Sell
73,333
-6,667
-8% -$1.93M 2.6% 6
2019
Q3 		$21.9M Buy
80,000
+31,667
+66% +$11.6M 2.74% 6
2019
Q2 		$25.8M Sell
48,333
-630
-1% -$316K 2.84% 6
2019
Q1 		$24.7M Buy
48,963
+14,630
+43% +$8.67M 2.89% 7
2018
Q4 		$16.9M Buy
34,333
+13,973
+69% +$8.43M 1.94% 19
2018
Q3 		$18.6M Sell
20,360
-20,817
-51% -$17.8M 1.87% 19
2018
Q2 		$30.2M Buy
41,177
+27,346
+198% +$31.5M 3.09% 1
2018
Q1 		$22M Sell
13,831
-9,736
-41% -$12.5M 2.72% 8
2017
Q4 		$21.1M Sell
23,567
-34,179
-59% -$20.2M 2.85% 6
2017
Q3 		$20.8M Buy
57,746
+4,746
+9% +$1.48M 2.65% 8
2017
Q2 		$15.5M Buy
53,000
+21,667
+69% +$6.26M 2.23% 12
2017
Q1 		$11M Buy
31,333
+4,000
+15% +$899K 1.75% 19
2016
Q4 		$5.03M Buy
27,333
+1,333
+5% +$271K 0.96% 40
2016
Q3 		$6.7M Sell
26,000
-5,333
-17% -$1.37M 1.06% 34
2016
Q2 		$6.69M Sell
31,333
-3,667
-10% -$820K 1.19% 28
2016
Q1 		$7.22M Sell
35,000
-3,733
-10% -$717K 1.43% 31
2015
Q4 		$9.79M Sell
38,733
-7,134
-16% -$1.47M 1.48% 30
2015
Q3 		$7.54M Sell
45,867
-16,600
-27% -$2.94M 1.2% 35
2015
Q2 		$11.7M Sell
62,467
-3,973
-6% -$684K 1.41% 20
2015
Q1 		$11M Buy
66,440
+50,573
+319% +$10.4M 1.85% 17
2014
Q4 		$3.69M Sell
15,867
-18,000
-53% -$3.85M 1.07% 31
2014
Q3 		$6.13M Buy
33,867
+16,534
+95% +$3.16M 1.8% 13
2014
Q2 		$3.33M Buy
17,333
+5,213
+43% +$922K 0.99% 32
2014
Q1 		$2.2M Sell
12,120
-547
-4% -$108K 0.66% 55
2013
Q4 		$2.16M Buy
+12,667
New +$2.04M 0.84% 52

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Rhenman & Partners Asset Management's NKTR Position: Q1 2026 in Review

Rhenman & Partners Asset Management opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 59,000 shares worth $4.25M. The stake represents 0.52% of the portfolio and ranks #63 among its holdings. This is a return to the name: Rhenman & Partners Asset Management previously reported a position in NKTR as recently as Q4 2022.

Rhenman & Partners Asset Management first reported a position in NKTR in Q4 2013 and has held it in 38 quarters since. The position peaked at $30.2M in Q2 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Rhenman & Partners Asset Management held 59,000 shares of Nektar Therapeutics worth $4.25M as of Q1 2026.
  • Nektar Therapeutics was a new Rhenman & Partners Asset Management position in Q1 2026.
  • Nektar Therapeutics made up 0.52% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #63 holding.
  • Rhenman & Partners Asset Management first reported a position in Nektar Therapeutics in Q4 2013 and has held it in 38 quarters since.
  • Rhenman & Partners Asset Management's Nektar Therapeutics position peaked at $30.2M in Q2 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.